Abstract
Randomized controlled clinical trials are felt by the medical community to provide the best evidence. Participation in trials involves the possibility of obtaining benefits but also of suffering some risks. Those risks are often considered unacceptable for children but if clinical trials are not conducted in children, clinicians are forced to extrapolate study data from adults. In 1968 H. Shirkey termed children “therapeutic orphans” because of the lack of adequately tested and labeled drugs available in appropriate formulations. Research involving children entails specific difficulties as the need to study children of different ages, the small number of children affected by certain diseases or ethical issues. This paper considers aspects of pediatric clinical pharmacology and childrens responses to drugs. It also reviews some of the current situations in pediatric clinical trials, covering aspects such as: the benefits and risks of trial participation; the specificity of pediatric trial design; the ethical issues such as consent; the use of placebo or the participation of healthy children; and the current legal situation in Europe and in the USA.
Keywords: randomized controlled trials, Ethical issues, Institutional Review Boards (IRB), Pediatric Research Equity Act (PREA), FDAMA, Pediatric Clinical Research
Reviews on Recent Clinical Trials
Title: Clinical Trials in Children
Volume: 1 Issue: 3
Author(s): F. J. Morales-Olivas and C. Morales-Carpi
Affiliation:
Keywords: randomized controlled trials, Ethical issues, Institutional Review Boards (IRB), Pediatric Research Equity Act (PREA), FDAMA, Pediatric Clinical Research
Abstract: Randomized controlled clinical trials are felt by the medical community to provide the best evidence. Participation in trials involves the possibility of obtaining benefits but also of suffering some risks. Those risks are often considered unacceptable for children but if clinical trials are not conducted in children, clinicians are forced to extrapolate study data from adults. In 1968 H. Shirkey termed children “therapeutic orphans” because of the lack of adequately tested and labeled drugs available in appropriate formulations. Research involving children entails specific difficulties as the need to study children of different ages, the small number of children affected by certain diseases or ethical issues. This paper considers aspects of pediatric clinical pharmacology and childrens responses to drugs. It also reviews some of the current situations in pediatric clinical trials, covering aspects such as: the benefits and risks of trial participation; the specificity of pediatric trial design; the ethical issues such as consent; the use of placebo or the participation of healthy children; and the current legal situation in Europe and in the USA.
Export Options
About this article
Cite this article as:
Morales-Olivas J. F. and Morales-Carpi C., Clinical Trials in Children, Reviews on Recent Clinical Trials 2006; 1 (3) . https://dx.doi.org/10.2174/157488706778250087
DOI https://dx.doi.org/10.2174/157488706778250087 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Mechanisms of Anti-cancer Action of Garlic Compounds in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry CIITA and the MHCII Enhanceosome in the Regulation of MHCII Expression
Current Genomics Coumarin and Derivates as Lipid Lowering Agents
Current Topics in Medicinal Chemistry IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design Iron Chelators in Cancer Chemotherapy
Current Topics in Medicinal Chemistry Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy Personalizing Medicine from Birth: Are Countries Prepared for the Ethical, Legal, and Social Challenges?
Current Pharmacogenomics and Personalized Medicine Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety Stress, Depression and Hippocampal Apoptosis
CNS & Neurological Disorders - Drug Targets Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets Interventional Radiology Procedures: Current Issues in Patient Doses and Image Quality Optimization
Current Medical Imaging γ δ T Cells and Dendritic Cells: Close Partners and Biological Adjuvants for New Therapies
Current Molecular Medicine The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design Relevance of Vitamin D in Bone and Muscle Health of Cancer Patients
Anti-Cancer Agents in Medicinal Chemistry Polymorphism of UDP-Glucuronosyltransferase and Drug Metabolism
Current Drug Metabolism Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy
Current Genomics Comparative Binding Mode and Residual Contribution from Lactoferrins (bLF and hLF) and HIV Gp120: An In silico Structural Perspective to Design Potent Peptide Inhibitor for HIV
Current Enzyme Inhibition Electrical Impedance Scanning - A New Diagnostic Tool in Cancer Detection: Current Status and Recent Developments
Current Medical Imaging Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science